{ "kind": "framework", "value": "kaplan-meier-survival-analysis", "collectionKey": "slides:framework:kaplan-meier-survival-analysis:all-document-kinds:all-producers:all-orientations", "filters": { "documentKinds": [], "sourceTypes": [], "orientations": [] }, "total": 19, "page": 1, "pageSize": 24, "pageCount": 1, "rows": [ { "docId": "019de071-753f-7227-aa1d-36a319c59353", "docSlug": "7013d0966bfedd0d757b9fa24a480455", "documentTitle": "AstraZeneca | Investor Day Presentation Deck | 34 slides", "authorId": "astrazeneca", "authorName": "AstraZeneca", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2021-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 12, "slideType": "appendix_data", "function": "analyze_data", "notes": "Kaplan-Meier survival analysis plot with a risk table below.", "imagePath": null, "matchCount": 1, "evidence": "Standard clinical trial visualization for time-to-event data", "slideHref": "/slides/019de071-753f-7227-aa1d-36a319c59353/12", "deckHref": "/decks/019de071-753f-7227-aa1d-36a319c59353", "deckAnchorHref": "/decks/019de071-753f-7227-aa1d-36a319c59353#slide-12", "loopMatches": [ { "to": 17, "from": 6, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "f6f774ca-af54-4b25-aa3a-3b940b789d31", "evidence": "The deck highlights the limitations of current treatments and Enhertu's potential to improve patient outcomes.", "position": 0, "objective": "What are the consequences of not adopting Enhertu as the standard of care?", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.7, "description": "Quantify what happens if the audience does nothing" }, { "to": 14, "from": 9, "name": "Hypothesis Test", "slug": "42-hypothesis-test", "bestFor": "Strategy validation, due diligence, research presentations", "matchId": "4c136f41-d14c-4c9d-b4d4-01b2328be5bb", "evidence": "The deck presents detailed trial data to support Enhertu's efficacy and safety.", "position": 1, "objective": "How does Enhertu's data support its potential as a standard of care?", "structure": "The Hypothesis -> Test 1 (Supports/Refutes) -> Test 2 (Supports/Refutes) -> Conclusion (Validated/Pivoted)", "confidence": 0.7, "description": "State a hypothesis upfront, then systematically prove or disprove it with evidence" } ], "arcBeatMatches": [ { "to": 14, "from": 9, "beatId": "7d6fc11c-9c63-4d02-bc07-8fe706170a68", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Product", "beatSlug": "sequoia-pitch-product", "evidence": "Detailed data on Enhertu's efficacy and safety", "position": 1, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de071-753f-7227-aa1d-36a319c59353", "docSlug": "7013d0966bfedd0d757b9fa24a480455", "documentTitle": "AstraZeneca | Investor Day Presentation Deck | 34 slides", "authorId": "astrazeneca", "authorName": "AstraZeneca", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2021-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 13, "slideType": "appendix_data", "function": "analyze_data", "notes": "Kaplan-Meier survival analysis plot with a risk table at the bottom.", "imagePath": null, "matchCount": 1, "evidence": "Standard clinical trial visualization for time-to-event data", "slideHref": "/slides/019de071-753f-7227-aa1d-36a319c59353/13", "deckHref": "/decks/019de071-753f-7227-aa1d-36a319c59353", "deckAnchorHref": "/decks/019de071-753f-7227-aa1d-36a319c59353#slide-13", "loopMatches": [ { "to": 17, "from": 6, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "f6f774ca-af54-4b25-aa3a-3b940b789d31", "evidence": "The deck highlights the limitations of current treatments and Enhertu's potential to improve patient outcomes.", "position": 0, "objective": "What are the consequences of not adopting Enhertu as the standard of care?", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.7, "description": "Quantify what happens if the audience does nothing" }, { "to": 14, "from": 9, "name": "Hypothesis Test", "slug": "42-hypothesis-test", "bestFor": "Strategy validation, due diligence, research presentations", "matchId": "4c136f41-d14c-4c9d-b4d4-01b2328be5bb", "evidence": "The deck presents detailed trial data to support Enhertu's efficacy and safety.", "position": 1, "objective": "How does Enhertu's data support its potential as a standard of care?", "structure": "The Hypothesis -> Test 1 (Supports/Refutes) -> Test 2 (Supports/Refutes) -> Conclusion (Validated/Pivoted)", "confidence": 0.7, "description": "State a hypothesis upfront, then systematically prove or disprove it with evidence" } ], "arcBeatMatches": [ { "to": 14, "from": 9, "beatId": "7d6fc11c-9c63-4d02-bc07-8fe706170a68", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Product", "beatSlug": "sequoia-pitch-product", "evidence": "Detailed data on Enhertu's efficacy and safety", "position": 1, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de072-1970-7036-9d15-9ffed6304914", "docSlug": "3db8307bc8c7b92a71fc075519a1ccaf", "documentTitle": "AstraZeneca | Investor Day Presentation Deck | 35 slides", "authorId": "astrazeneca", "authorName": "AstraZeneca", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2022-02-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 12, "slideType": "kpi_overview", "function": "analyze_data", "notes": "Clinical trial data presentation; includes hazard ratio and median rPFS comparison.", "imagePath": null, "matchCount": 1, "evidence": "Standard clinical trial visualization for time-to-event data", "slideHref": "/slides/019de072-1970-7036-9d15-9ffed6304914/12", "deckHref": "/decks/019de072-1970-7036-9d15-9ffed6304914", "deckAnchorHref": "/decks/019de072-1970-7036-9d15-9ffed6304914#slide-12", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de072-1970-7036-9d15-9ffed6304914", "docSlug": "3db8307bc8c7b92a71fc075519a1ccaf", "documentTitle": "AstraZeneca | Investor Day Presentation Deck | 35 slides", "authorId": "astrazeneca", "authorName": "AstraZeneca", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2022-02-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 13, "slideType": "before_after", "function": "analyze_data", "notes": "The slide uses a Kaplan-Meier plot to visualize time-to-event data for a clinical trial.", "imagePath": null, "matchCount": 1, "evidence": "Standard clinical trial visualization for time-to-event data", "slideHref": "/slides/019de072-1970-7036-9d15-9ffed6304914/13", "deckHref": "/decks/019de072-1970-7036-9d15-9ffed6304914", "deckAnchorHref": "/decks/019de072-1970-7036-9d15-9ffed6304914#slide-13", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de074-15c9-703f-ba69-83bd63385db9", "docSlug": "61dc585c6c50f6919636d426c025da60", "documentTitle": "AstraZeneca | Investor Event Presentation Deck | 42 slides", "authorId": "astrazeneca", "authorName": "AstraZeneca", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2022-12-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 22, "slideType": "before_after", "function": "analyze_data", "notes": "The slide uses a standard Kaplan-Meier survival analysis framework common in oncology clinical trials.", "imagePath": null, "matchCount": 1, "evidence": "Standard clinical trial survival curve visualization", "slideHref": "/slides/019de074-15c9-703f-ba69-83bd63385db9/22", "deckHref": "/decks/019de074-15c9-703f-ba69-83bd63385db9", "deckAnchorHref": "/decks/019de074-15c9-703f-ba69-83bd63385db9#slide-22", "loopMatches": [ { "to": 25, "from": 22, "name": "Before After", "slug": "21-before-after", "bestFor": "Product demos, process improvements, ROI justification", "matchId": "756e3074-1834-4f75-af20-e818e2b60802", "evidence": "SERENA-2 trial data", "position": 1, "objective": "How does SERENA-2 address patient needs?", "structure": "The Old Way (Pain) -> The Moment of Change -> The New Way (Glory) -> The Measurable Delta", "confidence": 0.7, "description": "Show the dramatic contrast between the old way and the new way through side-by-side comparison" } ], "arcBeatMatches": [ { "to": 29, "from": 19, "beatId": "a90ff87c-6a94-47ae-8622-c8e4ab68f4ea", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Evidence & Proof", "beatSlug": "consultants-gambit-evidence-proof", "evidence": "SERENA-2 trial data and conclusions", "position": 3, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de074-15c9-703f-ba69-83bd63385db9", "docSlug": "61dc585c6c50f6919636d426c025da60", "documentTitle": "AstraZeneca | Investor Event Presentation Deck | 42 slides", "authorId": "astrazeneca", "authorName": "AstraZeneca", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2022-12-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 24, "slideType": "kpi_overview", "function": "analyze_data", "notes": "Clinical trial data visualization showing progression-free survival (PFS) curves with associated hazard ratios and event counts.", "imagePath": null, "matchCount": 1, "evidence": "Survival curves with censored data points and risk tables", "slideHref": "/slides/019de074-15c9-703f-ba69-83bd63385db9/24", "deckHref": "/decks/019de074-15c9-703f-ba69-83bd63385db9", "deckAnchorHref": "/decks/019de074-15c9-703f-ba69-83bd63385db9#slide-24", "loopMatches": [ { "to": 25, "from": 22, "name": "Before After", "slug": "21-before-after", "bestFor": "Product demos, process improvements, ROI justification", "matchId": "756e3074-1834-4f75-af20-e818e2b60802", "evidence": "SERENA-2 trial data", "position": 1, "objective": "How does SERENA-2 address patient needs?", "structure": "The Old Way (Pain) -> The Moment of Change -> The New Way (Glory) -> The Measurable Delta", "confidence": 0.7, "description": "Show the dramatic contrast between the old way and the new way through side-by-side comparison" } ], "arcBeatMatches": [ { "to": 29, "from": 19, "beatId": "a90ff87c-6a94-47ae-8622-c8e4ab68f4ea", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Evidence & Proof", "beatSlug": "consultants-gambit-evidence-proof", "evidence": "SERENA-2 trial data and conclusions", "position": 3, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-1718-756f-8ae4-37f1cf0d16ed", "docSlug": "2a95ead0d9ef429fb8fb8c2cc4a7d704", "documentTitle": "AstraZeneca | Investor Event Presentation Deck | 52 slides", "authorId": "astrazeneca", "authorName": "AstraZeneca", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-06-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 15, "slideType": "appendix_data", "function": "analyze_data", "notes": "Clinical trial data visualization (Kaplan-Meier plot).", "imagePath": null, "matchCount": 1, "evidence": "Survival curve plot with 'No. at risk' table", "slideHref": "/slides/019de075-1718-756f-8ae4-37f1cf0d16ed/15", "deckHref": "/decks/019de075-1718-756f-8ae4-37f1cf0d16ed", "deckAnchorHref": "/decks/019de075-1718-756f-8ae4-37f1cf0d16ed#slide-15", "loopMatches": [ { "to": 25, "from": 15, "name": "Before After", "slug": "21-before-after", "bestFor": "Product demos, process improvements, ROI justification", "matchId": "b41eaf1b-437d-4b91-9988-0e6fb0f284a8", "evidence": "The deck presents data and results from various trials, showcasing the company's progress in oncology", "position": 1, "objective": "What are the benefits of AstraZeneca's pipeline?", "structure": "The Old Way (Pain) -> The Moment of Change -> The New Way (Glory) -> The Measurable Delta", "confidence": 0.7, "description": "Show the dramatic contrast between the old way and the new way through side-by-side comparison" } ], "arcBeatMatches": [ { "to": 25, "from": 15, "beatId": "ba7e7aa9-525b-4e2a-a4f1-214ecf8f098d", "arcName": "Monroe's Motivated Sequence", "arcSlug": "monroes-sequence", "beatName": "Satisfaction", "beatSlug": "monroes-sequence-satisfaction", "evidence": "The deck presents data and results from various trials, showcasing the company's progress in oncology", "position": 2, "confidence": 0.8, "parentBeatName": "Turn", "parentBeatSlug": "turn" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-1718-756f-8ae4-37f1cf0d16ed", "docSlug": "2a95ead0d9ef429fb8fb8c2cc4a7d704", "documentTitle": "AstraZeneca | Investor Event Presentation Deck | 52 slides", "authorId": "astrazeneca", "authorName": "AstraZeneca", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-06-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 32, "slideType": "before_after", "function": "analyze_data", "notes": "Clinical trial data presentation showing PFS outcomes for Arm 1 (chemo + bev) vs Arm 3 (chemo + bev + durvalumab + olaparib).", "imagePath": null, "matchCount": 1, "evidence": "Visual representation of survival probability over time with censored data points.", "slideHref": "/slides/019de075-1718-756f-8ae4-37f1cf0d16ed/32", "deckHref": "/decks/019de075-1718-756f-8ae4-37f1cf0d16ed", "deckAnchorHref": "/decks/019de075-1718-756f-8ae4-37f1cf0d16ed#slide-32", "loopMatches": [], "arcBeatMatches": [ { "to": 52, "from": 26, "beatId": "a55635e0-23e3-4936-80d1-f995ad7f0061", "arcName": "Monroe's Motivated Sequence", "arcSlug": "monroes-sequence", "beatName": "Action", "beatSlug": "monroes-sequence-action", "evidence": "The deck concludes with a roadmap for future growth, potential new options for patients, and a summary of key messages", "position": 3, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-1718-756f-8ae4-37f1cf0d16ed", "docSlug": "2a95ead0d9ef429fb8fb8c2cc4a7d704", "documentTitle": "AstraZeneca | Investor Event Presentation Deck | 52 slides", "authorId": "astrazeneca", "authorName": "AstraZeneca", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-06-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 33, "slideType": "appendix_data", "function": "analyze_data", "notes": "Clinical trial data presentation using Kaplan-Meier plots with associated risk tables and hazard ratios.", "imagePath": null, "matchCount": 1, "evidence": "Survival curves with at-risk tables", "slideHref": "/slides/019de075-1718-756f-8ae4-37f1cf0d16ed/33", "deckHref": "/decks/019de075-1718-756f-8ae4-37f1cf0d16ed", "deckAnchorHref": "/decks/019de075-1718-756f-8ae4-37f1cf0d16ed#slide-33", "loopMatches": [], "arcBeatMatches": [ { "to": 52, "from": 26, "beatId": "a55635e0-23e3-4936-80d1-f995ad7f0061", "arcName": "Monroe's Motivated Sequence", "arcSlug": "monroes-sequence", "beatName": "Action", "beatSlug": "monroes-sequence-action", "evidence": "The deck concludes with a roadmap for future growth, potential new options for patients, and a summary of key messages", "position": 3, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de072-b09f-7797-83e5-c925df87e1b3", "docSlug": "fb96dc8e32131cd826524e728a742819", "documentTitle": "Compass Therapeutics | Investor Presentation Deck | 36 slides", "authorId": "compass-therapeutics", "authorName": "Compass Therapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2022-05-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 14, "slideType": "appendix_data", "function": "analyze_data", "notes": "Clinical trial data presented at ASCO GI 2022.", "imagePath": null, "matchCount": 1, "evidence": "Standard clinical trial visualization for time-to-event data", "slideHref": "/slides/019de072-b09f-7797-83e5-c925df87e1b3/14", "deckHref": "/decks/019de072-b09f-7797-83e5-c925df87e1b3", "deckAnchorHref": "/decks/019de072-b09f-7797-83e5-c925df87e1b3#slide-14", "loopMatches": [], "arcBeatMatches": [ { "to": 17, "from": 6, "beatId": "4553c68f-c8a6-4cb5-9d28-9bc65dfd58fa", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Problem", "beatSlug": "problem-agitate-solution-problem-identify-pain", "evidence": "Slides 6-17 identify the problem, highlighting the unmet needs in BTC treatment.", "position": 0, "confidence": 0.8, "parentBeatName": "Complication", "parentBeatSlug": "complication" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-f154-767b-9f07-479a2da3f64b", "docSlug": "d4796e91221d5758021de97ee63957e0", "documentTitle": "Exscientia | Investor Presentation Deck | 69 slides", "authorId": "exscientia", "authorName": "Exscientia", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-10-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 18, "slideType": "traction", "function": "show_traction", "notes": "The slide uses Kaplan-Meier curves to demonstrate clinical efficacy of the platform's drug prioritization.", "imagePath": null, "matchCount": 1, "evidence": "Standard clinical trial methodology for time-to-event data", "slideHref": "/slides/019de075-f154-767b-9f07-479a2da3f64b/18", "deckHref": "/decks/019de075-f154-767b-9f07-479a2da3f64b", "deckAnchorHref": "/decks/019de075-f154-767b-9f07-479a2da3f64b#slide-18", "loopMatches": [ { "to": 69, "from": 3, "name": "Golden Circle", "slug": "11-golden-circle", "bestFor": "Visionary leadership, brand positioning, mission statements", "matchId": "89204827-3a6d-41c5-9676-a9c3c4bc7a6d", "evidence": "The deck presents Exscientia's approach to precision medicine, highlighting its effectiveness.", "position": 1, "objective": "Why is Exscientia's approach to precision medicine effective?", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "confidence": 0.7, "description": "Invert the typical pitch by starting with why you exist, rather than what you do" } ], "arcBeatMatches": [ { "to": 69, "from": 8, "beatId": "96bf0b4a-a49b-4aee-bb3c-8a6ad1f87eda", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Solution (Provide relief)", "beatSlug": "problem-agitate-solution-solution-provide-relief", "evidence": "The deck presents Exscientia's solution, highlighting its AI-driven platform and its potential to improve clinical trial success rates.", "position": 2, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-4aec-72cf-a6e0-519f4b0af11c", "docSlug": "80e6ab6db3df4d91b63f99a2a4cf6dc3", "documentTitle": "Exscientia | Investor Presentation Deck | 73 slides", "authorId": "exscientia", "authorName": "Exscientia", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-07-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 17, "slideType": "traction", "function": "show_traction", "notes": "Includes Kaplan-Meier survival curves and a clinical decision pathway diagram.", "imagePath": null, "matchCount": 1, "evidence": "Standard clinical trial visualization for time-to-event data", "slideHref": "/slides/019de075-4aec-72cf-a6e0-519f4b0af11c/17", "deckHref": "/decks/019de075-4aec-72cf-a6e0-519f4b0af11c", "deckAnchorHref": "/decks/019de075-4aec-72cf-a6e0-519f4b0af11c#slide-17", "loopMatches": [ { "to": 73, "from": 5, "name": "Cost Of Inaction", "slug": "27-cost-of-inaction", "bestFor": "Urgent budget requests, compliance, risk mitigation", "matchId": "02ebf716-8af1-4eca-8937-1321b5d2471c", "evidence": "The deck presents the consequences of not adopting Exscientia's technology throughout the presentation", "position": 0, "objective": "What is the cost of not adopting Exscientia's AI-driven precision medicine platform?", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "confidence": 0.8, "description": "Quantify what happens if the audience does nothing" } ], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de075-8d44-7401-b489-ee436db9a207", "docSlug": "66ec60e76d61a423395d466c32dc56fb", "documentTitle": "Exscientia | Investor Presentation Deck | 75 slides", "authorId": "exscientia", "authorName": "Exscientia", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-08-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 17, "slideType": "traction", "function": "show_traction", "notes": "Kaplan-Meier survival analysis showing statistically significant improvement in PFS for matched treatments.", "imagePath": null, "matchCount": 1, "evidence": "Standard clinical trial visualization for time-to-event data", "slideHref": "/slides/019de075-8d44-7401-b489-ee436db9a207/17", "deckHref": "/decks/019de075-8d44-7401-b489-ee436db9a207", "deckAnchorHref": "/decks/019de075-8d44-7401-b489-ee436db9a207#slide-17", "loopMatches": [], "arcBeatMatches": [ { "to": 18, "from": 16, "beatId": "6df3077d-ba17-4dfd-9e88-6df7d6b72734", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Evidence & Proof", "beatSlug": "consultants-gambit-evidence-proof", "evidence": "EXALT-1 study results", "position": 4, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-3901-734c-833f-b5b0e2d3aa41", "docSlug": "e86c5f257c7f518e1f9c16c922f96c7d", "documentTitle": "Exscientia | Investor Presentation Deck | 76 slides", "authorId": "exscientia", "authorName": "Exscientia", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-11-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 18, "slideType": "traction", "function": "show_traction", "notes": "The slide uses Kaplan-Meier curves to demonstrate clinical efficacy of the platform's drug prioritization.", "imagePath": null, "matchCount": 1, "evidence": "Standard clinical trial methodology for time-to-event data", "slideHref": "/slides/019de076-3901-734c-833f-b5b0e2d3aa41/18", "deckHref": "/decks/019de076-3901-734c-833f-b5b0e2d3aa41", "deckAnchorHref": "/decks/019de076-3901-734c-833f-b5b0e2d3aa41#slide-18", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de077-0326-7579-845c-ff13347b3147", "docSlug": "a6759fd47798a8f3f6e744ad8917865e", "documentTitle": "Exscientia | Investor Presentation Deck | 93 slides", "authorId": "exscientia", "authorName": "Exscientia", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2024-03-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 41, "slideType": "traction", "function": "show_traction", "notes": "The slide uses Kaplan-Meier curves to demonstrate clinical efficacy of the platform's drug prioritization.", "imagePath": null, "matchCount": 1, "evidence": "Visual representation of survival probability over time", "slideHref": "/slides/019de077-0326-7579-845c-ff13347b3147/41", "deckHref": "/decks/019de077-0326-7579-845c-ff13347b3147", "deckAnchorHref": "/decks/019de077-0326-7579-845c-ff13347b3147#slide-41", "loopMatches": [], "arcBeatMatches": [ { "to": 76, "from": 40, "beatId": "5ac1e19c-a020-4b03-85c5-f8d4af660d2d", "arcName": "The Sparkline", "arcSlug": "sparkline", "beatName": "Traction", "beatSlug": null, "evidence": "Highlighting of Exscientia's achievements and partnerships", "position": 3, "confidence": 0.8, "parentBeatName": null, "parentBeatSlug": null } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de071-805e-75da-a9c3-e9573cb6e94f", "docSlug": "f179c2894ff7ef65a3c6d24dd4bec442", "documentTitle": "Exscientia | IPO Presentation Deck | 60 slides", "authorId": "exscientia", "authorName": "Exscientia", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investment_bank", "sourceTypeLabel": "Investment bank", "presentationDate": "2021-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7893755, "pageNumber": 18, "slideType": "traction", "function": "show_traction", "notes": "Includes Kaplan-Meier survival curves and hazard ratios (HR) from a study published in The Lancet Haematology.", "imagePath": null, "matchCount": 1, "evidence": "Clinical survival curves comparing matched vs non-matched treatment", "slideHref": "/slides/019de071-805e-75da-a9c3-e9573cb6e94f/18", "deckHref": "/decks/019de071-805e-75da-a9c3-e9573cb6e94f", "deckAnchorHref": "/decks/019de071-805e-75da-a9c3-e9573cb6e94f#slide-18", "loopMatches": [ { "to": 60, "from": 4, "name": "Golden Circle", "slug": "11-golden-circle", "bestFor": "Visionary leadership, brand positioning, mission statements", "matchId": "3b6b60bf-18b7-4458-bffa-eba1b1ca0583", "evidence": "The deck presents a comprehensive loop on the golden circle of problem-solution-benefit.", "position": 1, "objective": "Explain how Exscientia's AI-driven platform can solve the problem of inefficient drug discovery.", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "confidence": 0.7, "description": "Invert the typical pitch by starting with why you exist, rather than what you do" } ], "arcBeatMatches": [ { "to": 60, "from": 4, "beatId": "5dda98c6-c560-4b21-aa1c-95b617a27a20", "arcName": "The Sequoia Pitch", "arcSlug": "sequoia-pitch", "beatName": "Solution", "beatSlug": "sequoia-pitch-solution", "evidence": "The deck presents a comprehensive solution throughout pages 4-60.", "position": 1, "confidence": 0.8, "parentBeatName": "Turn", "parentBeatSlug": "turn" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-5fed-74f2-a96e-5b9c36e08179", "docSlug": "bi-55e1ed4cb75ab283", "documentTitle": "Faeth Therapeutics Series A pitch deck: $47 million to fight cancer", "authorId": "Pitchdecks", "authorName": "Faeth Therapeutics", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "strategy_consulting", "sourceTypeLabel": "Strategy consulting", "presentationDate": null, "orientation": "landscape", "aspectRatio": 1.785, "pageNumber": 6, "slideType": "traction", "function": "show_traction", "notes": "The chart is a classic Kaplan-Meier survival plot used in oncology research.", "imagePath": null, "matchCount": 1, "evidence": "Standard survival curve visualization for oncology", "slideHref": "/slides/019dd923-5fed-74f2-a96e-5b9c36e08179/6", "deckHref": "/decks/019dd923-5fed-74f2-a96e-5b9c36e08179", "deckAnchorHref": "/decks/019dd923-5fed-74f2-a96e-5b9c36e08179#slide-6", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de076-4a3e-76ed-83f8-e348223f91d9", "docSlug": "c1eecdcf261eded4e99ffa840c30e475", "documentTitle": "Immix Biopharma | Investor Presentation Deck | 60 slides", "authorId": "immix-biopharma", "authorName": "Immix Biopharma", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-11-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 47, "slideType": "traction", "function": "show_traction", "notes": "Includes Kaplan-Meier survival curves and bioluminescence imaging of tumor activity.", "imagePath": null, "matchCount": 1, "evidence": "Survival curves for preclinical mouse models", "slideHref": "/slides/019de076-4a3e-76ed-83f8-e348223f91d9/47", "deckHref": "/decks/019de076-4a3e-76ed-83f8-e348223f91d9", "deckAnchorHref": "/decks/019de076-4a3e-76ed-83f8-e348223f91d9#slide-47", "loopMatches": [ { "to": 60, "from": 3, "name": "Golden Circle", "slug": "11-golden-circle", "bestFor": "Visionary leadership, brand positioning, mission statements", "matchId": "50c25ad2-0c48-4213-947d-b362da490be1", "evidence": "The deck presents a 'why' (N-GENIUS platform), 'how' (technology overview), and 'what' (clinical results) narrative", "position": 1, "objective": "Why is Immix Biopharma's N-GENIUS platform important?", "structure": "The Why (Belief) -> The How (Process) -> The What (Result)", "confidence": 0.7, "description": "Invert the typical pitch by starting with why you exist, rather than what you do" } ], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019de073-9523-714b-a2b4-ffafcdbd0ef0", "docSlug": "bc9bef6f52d4d9603180b6eb6c4f9d10", "documentTitle": "SAB Biotherapeutics | Results Presentation Deck | 12 slides", "authorId": "sab-biotherapeutics", "authorName": "SAB Biotherapeutics", "documentKindSlug": "regulatory-filing", "documentKindLabel": "Regulatory filing", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2022-09-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 10, "slideType": "appendix_data", "function": "analyze_data", "notes": "The chart shows a clear separation between the treatment and placebo groups, indicating faster viral clearance in the treatment arm.", "imagePath": null, "matchCount": 1, "evidence": "Standard statistical method for time-to-event data", "slideHref": "/slides/019de073-9523-714b-a2b4-ffafcdbd0ef0/10", "deckHref": "/decks/019de073-9523-714b-a2b4-ffafcdbd0ef0", "deckAnchorHref": "/decks/019de073-9523-714b-a2b4-ffafcdbd0ef0#slide-10", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true } ] }